Lilly’s 2013 profit forecast tops expectations
Eli Lilly and Co. forecasts its 2013 earnings will grow more than Wall Street expects even though the drugmaker will lose U.S. patent protection for two more key products in the new year.
Health Care & Insurance
Articles
Trial set to begin over pregnancy drug sold by Lilly
Four sisters diagnosed with breast cancer are suing Eli Lilly and Co., a former maker of DES, or diethylstilbestrol, a drug taken by their mother in the 1950s when she was pregnant. It could be the first of scores of such trials over the drug.
Decline in fitness club memberships pushes NIFS into arms of seniors
Health club on campus of IUPUI makes up for lost revenue by managing fitness and wellness programs for retirement communities.
CNO’s Bonach has insurance firm back on offense
CNO Financial Group’s stock price has nearly doubled since Ed Bonach took the helm in October 2011. Some analysts that follow the successor to Conseco Inc., which a decade ago was the nation’s third-largest Chapter 11 bankruptcy reorganization, now regard CNO as an attractive value play.
Stock buyback continues at CNO
The Carmel-based owner of Bankers Life and other insurance companies has seen its stock rise as it restructures debt.
Fort Wayne church insurer plans to add 102 jobs
Brotherhood Mutual Insurance Co. expects to hire the employees by 2016 as part of a $15 million expansion that includes building a 54,395-square-foot facility at its headquarters.
WellPoint completes $4.5B Amerigroup acquisition
The deal gives the Indianapolis insurer a bigger slice of the growing market of patients covered by Medicaid, the federal-state health program for low-income people.
Women’s physician building targeted for foreclosure
A lawsuit from the lender claims that Women’s Physician Group still owes $8.7 million on a $9 million loan it received for a northwest-side building.
Lilly agrees to pay $29.4M to settle SEC bribery charges
According to a statement released by the SEC, Eli Lilly paid $6.5 million—and in some cases gave jewelry and spa treatments—to win government contracts in Brazil, China, Russia and Poland.
Indiana to receive nearly $793K in Amgen settlement
Amgen Inc. has agreed to pay Indiana nearly $793,000 as part of a larger settlement to resolve allegations it paid kickbacks to physicians who prescribed some of its drugs for unapproved uses.
Lilly OKs $1.5B share buyback, first quarter dividend
Indianapolis-based drugmaker Eli Lilly and Co. said Monday that its board authorized a $1.5 billion share-repurchase program, which the company expects to complete next year.
Lilly finds solace in new Alzheimer’s study
Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.
Health care pricing service comes to Indy
Chicago-based OkCopay Inc. posts prices offered by Indianapolis health care providers, many of which have agreed to give cash-paying patients a price roughly equivalent to those charged to insured customers. The site also includes pricing information from health care providers that do not give cash-paying patients an additional break.
State expects to extend Healthy Indiana Plan a year
The Centers for Medicare and Medicaid Services agreed to a waiver that would allow the state to continue the program unchanged for a year.
Actuarial firm plans expansion at Indy office
Milliman Inc. said it will add 26 jobs by 2017 and invest $2 million to install additional information technology equipment at its office in downtown’s Chase Tower.
Apartments, shops planned for old Beech Grove hospital site
Dubbed Franciscan Place, the $20 million development will feature 150-plus senior-living apartments, shops and a restaurant in the old hospital. Work is expected to begin in February.
Lilly discontinues late-stage trial in rheumatoid arthritis
Eli Lilly and Co. said it discontinued a last-stage trial of experimental rheumatoid arthritis drug tabalumab for lack of efficacy. Lilly is still evaluating the drug in the two other late-stage studies.
Indiana to get $1.1 million in Pfizer settlement
The money is the state's share of a $42.9 million deal the drugmaker struck to resolve allegations it deceptively marketed an antibacterial agent and promoted a fibromyalgia treatment for off-label uses.
Lilly plans another study for Alzheimer’s drug
Eli Lilly will launch another study of its possible Alzheimer's treatment solanezumab, a move that delays a regulatory decision on a drug that flashed potential to help patients with mild cases of the fatal disease.
WellPoint reaffirms 2012 earnings forecast
WellPoint Inc. is sticking with a 2012 earnings forecast that it had cut in July, and the nation's second-largest health insurer said it expects next year's earnings to be on par with this year's performance.